The importance of the European Foundation for Clinical Nanomedicine
The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.
Nanotechnology for Medicine
Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimetre. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.
Establishing the INTRALAB-N
In its study on Nanomedicine the European Science Foundation shows that Europe currently takes the lead "in ultra-modern technology" in the field of Nanomedicine. In order to maintain this advanced position, in Europe there is high need for labs and research spaces as a fundamental condition to facilitate innovation across Europe, assisting to be a knowledge driven economy in the global market. The European Foundation for Clinical Nanomedicine plans to realise its project of the International Translational Laboratory for Nanomedicine (INTRALAB-N) in Basel, Switzerland. Basel is the location of many chemical and pharmaceutical companies. The town offers excellent scientific facilities with the Department of Research of the Basel University Hospital, the University Basel with its Biozentrum and private research places such as the Friedrich Miescher Institute. Basel is worldwide renown for its Swiss Nanoscience Institute (SNI) developed from the National Center of Competence in Research (NCCR) for Nanoscale Science. The project shall be in joint cooperation with five Universities in Europe
An important task is the establishment of the CLINAM-Foundation Network. Its purpose is the proactive support of development of Nanomedicine in Europe for all clinical experts in research and development of Nanomedicine including bridgework between the clinicians, academic research and the industrial and tool developing clusters. - The network interacts with the existing nanomedical structures in Europe, seeking to propagate nanomedical knowledge. The CLINAM-Network is a valuable non-competing add-on for the various other initiatives in the field of Nanomedicine. CLINAM became in the last years the melting pot for all stakeholders in Clinical Nanomedicine. The European Summit for Clinical Nanomedicine with more than 500 participants from more than 40 countries is the neutral platform where cooperation projects, application-concepts for Funding by the EU, start-up concepts and consortia are created. The presence at each Summit of the Regulatory Authorities from all Continents is a high value since all stakeholders have the opportunity to discuss the needs and hurdles in the translation of Nanomedicine and the debate creates trust between all related parties.
Establishing the INTRALAB-N
In its study on Nanomedicine the European Science Foundation shows that Europe currently takes the lead "in ultra-modern technology" in the field of Nanomedicine. In order to maintain this advanced position, in Europe, there is high need for labs and research spaces as a fundamental condition to facilitate innovation across Europe, assisting to be a knowledge driven economy in the global market.
The European Foundation for Clinical Nanomedicine has the vision to create in Switzerland a large translational Center for Nanomedicine and works in several Swiss initiatives to reach this goal. The working title that is given to the project is the “Intralab-for Nanomedicine”. It is also in relation to the mission of a European “one pipe” Characterization Lab to be established in Switzerland. This center is not in competition but a complementary project to projects by the EU to establish characterization-networks. As a first big step the CLINAM Foundaton has established in its Lab at Bernoullistrasse in Basel, closest to the University Hospital the CLINAM-Research Lab
Basel as Location of the Foundation
.Basel is the location of many chemical and pharmaceutical companies. The town offers excellent scientific facilities with the Department of Research of the Basel University Hospital, the University Basel with its Biozentrum and private research places such as the Friedrich Miescher Institute. Basel is worldwide renowned for its Swiss Nanoscience Institute (SNI) developed from the National Center of Competence in Research (NCCR) for Nanoscale Science. The project shall be in cooperation with five Universities in Europe. Also the recent NCCR of the University of Basel is also related to Nanotechnology. The goals set by the “NCCR Molecular Systems Engineering” is to make use of advances in chemistry, molecular cell biology and genetics, physics, bioinformatics and engineering to assemble functional molecular modules into complex systems.
Fundraising for Research and Development and Interaction of Excellence
Nanomedicine is at the edge of being applied in clinic to the treatment of the human being and therefore the need for investment into research is very high. - The foundation needs funding to novel research-investments that shall lead to major progress and shorten the developmental lag time in implementing translational nanomedicine and keeping Europe being a front runner in the development of nanomedicine in clinical use. The CLINAM Management is at any time ready to show its work and the research projects that are waiting to be tackled.
The Structure of the European Foundation for Clinical Nanomedicine
The European Foundation for Clinical Nanomedicine is a lean organization and seeks to keep the administration at an utmost minimum. Presently at the CLINAM Lab eight members work in Science. At the foundation thee people invest into the development of the Summit and the regular administration and are involved in the EU-Project Dissemination. In addition to this there are freelance members and members from the Board of Trustees who support the development of CLINAM with valuable input into the Programme of the Summit.
The Foundation is governed by its Board of Trustees.
- Dr. Alexander Gutmans (law) (President)
- Dr. med. h.c. Beat Löffler, MA (management and conference) (CEO)
- Prof. Dr. Patrick Hunziker (cardiovascular medicine/ Nanomedicine) (CSO)
- Prof. Dr. Jan Mollenhauer (molecular oncology)
- Prof. Dr. Gerrit Storm (pharmacology)
- Susy Hunziker, lic. Phil. (banking)
- Prof. Dr. Stefan Marsch (intensive care medicine)
Dr. med. h.c. Beat Löffler, MA is the CEO of the foundation and responsible for all organizational and administrative matters. He is the conceptor of the annual Summit for Clinical Nanomedicine and Targeted Medicine and responsible for the programme contents. He continuously shapes and enlarges the international Network for the Nanomedicine Community. Dr. Löffler is Editing Manager of the European Journal of Nanomedicine. He is Secretary General of the European Society for Nanomedicine. He is the Co-Founder of the European Foundation for Clinical Nanomedicine together with Prof. Dr. med. Patrick Hunziker
Prof. Dr. med. Patrick Hunziker is the CSO of the Foundation and responsible for all scientific matters and contents. He is leader of the CLINAM Research Lab and supervises the scientific quality of the annual Summit for Clinical Nanomedicine and Targeted Medicine. Prof. Dr. med Patrick Hunziker is Deputy Chief of the Intensive Care Unit of the University Hospital Basel. Prof. Hunziker is the Editor in Chief of the European Journal of Nanomedicine. (The second Editor in Chief is Prof. Dr. Jan Mollenhauer, *** who is also member of the Board of Trustees). Prof. Hunziker is President of the European Society for Nanomedicine as well as President of the International Society for Nanomedicine. He is the Co-Founder of the European Foundation for Clinical Nanomedicine together with Dr. med. h.c. Beat Löffler